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ABSTRACT
The clinical and epidemiological characteristics of 17 patients diagnosed with Mycobacterium kansasii
pneumonia within a limited geographical region over a period of 10 years are described. An in-depth
evaluation of the innate and adaptive immune systems was performed for five available patients. A
comparison was made of the genetic fingerprint patterns of the isolates obtained by restriction fragment
length polymorphism (RFLP) analysis, with the major polymorphic tandem repeat (MPTR) as a probe.
Predisposing factors consisted of smoking, airway abnormalities, substance abuse, diabetes or poor
general condition, but in two patients no risk factor was identified. In the five patients tested, no
abnormalities or deficiencies were detected in the innate or adaptive type-1 immunity. All M. kansasii
isolates had identical MPTR RFLP patterns, although no epidemiological connection could be
established, and these were identical to those of clinical isolates from Australian patients. These data
do not support the theory that defects in the innate or adaptive type-1 immunity have a role in the
pathogenesis of invasive M. kansasii infections. The identical fingerprint patterns of the isolates
suggested the existence of a virulent strain of M. kansasii.
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INTRODUCTION
Mycobacterium kansasii can cause lung infections
in apparently healthy subjects, unlike most other
environmental mycobacterial species which cause
illness almost exclusively in subjects with defects
in the cellular immune system as a result of
disease or immunosuppressive treatment [1].
M. kansasii pneumonia mimics classical lung
tuberculosis in many respects, which could reflect
similarities in the pathogenesis of these infections
caused by shared virulence factors of these
mycobacteria and similarities in host immunity
and susceptibility [2,3]. The relative importance of
characteristics of the microorganism, the host and
the environment in the pathogenesis of invasive
infection with M. kansasii in immunocompetent
subjects has not so far been elucidated.
The significant geographical variations seen in
the incidence of M. kansasii pneumonia, which
cannot be deduced simply from latitude or
climate, suggest that the environment is a rele-
vant factor [4,5]. A relatively high incidence of
M. kansasii pneumonia has been noted in certain
parts of the USA and in highly industrialised
regions of central Europe, the south-east of the
UK and the southern part of The Netherlands, all
of which were, at that time, mining and indus-
trial areas with heavy air pollution [6–9]. The
natural reservoir of M. kansasii is largely
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unknown, but has been postulated to include
water systems associated with habitation or
industry, since M. kansasii can be isolated from
such systems [10].
Extrapulmonary or disseminated M. kansasii
infections have been observed mainly in subjects
with compromised cellular immunity [4], inclu-
ding a small number of patients with mendelian
disorders of the interferon gamma (IFN-c) recep-
tor [9,11–13]. Invasive lung infection with
M. kansasii in the absence of a cellular immune
defect is often related to structurally abnormal
airways, associated with chronic obstructive pul-
monary disease, bronchiectasis or decreased mu-
cociliary clearance as a result of smoking or
exposure to heavy air pollution [9]. Particularly
when M. kansasii pneumonia occurs in an indi-
vidual without airway abnormalities and known
immune defects, the suspicion of an underlying
but as yet unrecognised immune defect arises.
However, detailed studies on type-1 cell-medi-
ated immunity against mycobacteria have not
been reported previously in patients suffer-
ing from isolated pulmonary infection with
M. kansasii.
An unusually high number of patients with
M. kansasii pneumonia has been observed previ-
ously in a former mining area in The Netherlands
[14]. The occurrence of this infection in a young
man with no risk factors for this infection promp-
ted an evaluation of all patients with documented
M. kansasii pneumonia who had been reported at
one regional health centre over a 10-year period.
This study describes the risk factors, clinical
presentation and epidemiological investigation
of 17 patients with M. kansasii pneumonia. All
causative M. kansasii isolates were genotyped and
fingerprint patterns were compared. The innate
and adaptive cellular immune systems of five
available patients were studied in detail.
PATIENTS AND METHODS
Patients
Patients were eligible if they had been diagnosed between 1991
and the end of 2001 withM. kansasii pneumonia in the absence
of a recognised immune defect, such as infection with HIV,
treatment with corticosteroids, other immunosuppressive
agents or chemotherapy. Although there is no central registry
in The Netherlands for M. kansasii infections, positive myco-
bacterial cultures are generally sent to the National Institute of
Public Health and the Environment in Bilthoven for species
identification and drug susceptibility testing. After adjustment
for multiple cultures ⁄patient, an unusually high number of
isolates appeared to originate from a limited geographical
region in the southern part of The Netherlands, namely the
former mining area in the southeastern part of the province of
Limburg. Patients from that region were recruited if they had
been recorded as suffering from M. kansasii pneumonia by the
Regional Health Authority in South Limburg. To discriminate
infection from colonisation, M. kansasii infection was defined
according to the criteria used by the American Thoracic Society
(ATS) [15]. In brief, these criteria require characteristic radio-
graphic abnormalities in combination with at least two positive
sputum cultures, plus one smear positive for acid-fast bacilli,
or three positive sputum cultures within 12 months, or at least
growth graded as 2+ from a bronchial wash, or characteristic
histology in a lung biopsy and at least one positive culture, in
the absence of an alternative diagnosis.
Demographic and clinical characteristics obtained retro-
spectively from the charts included age, sex, date of diagnosis,
profession, smoking habits, previous lung disease, extent and
results of contact investigations, presence or absence of
systemic symptoms, radiographic findings, result of acid-fast
staining, type of specimens cultured and number of positive
cultures, histology, duration and type of treatment and
outcome. Tuberculin skin test results and the results of skin
testing using tuberculin from M. kansasii (obtained from the
National Institute of Public Health and the Environment; the
availability of this product ceased in January 2003) were
recorded if these tests had been performed.
Genotyping of M. kansasii isolates and fingerprinting by
major polymorphic tandem repeats
M. kansasii isolates were typed by restriction fragment length
polymorphism (RFLP) analysis, with the major polymorphic
tandem repeat (MPTR) as a probe and PvuII as the restriction
enzyme [16]. Computer-assisted analysis of the MPTR patterns
was carried out with BioNumerics v. 3.0 (Applied Maths, St
Martens Latem, Belgium). The INNO-LiPA Mycobacteria
DNA probe test (Innogenetics, Ghent, Belgium), targeting the
16S)23S rRNA internally transcribed spacer sequence, was
used to identify M. kansasii internally transcribed spacer
sequence genotypes as described previously [17]. For compar-
ison, one M. tuberculosis reference strain, two other clinical
M. kansasii isolates from patients in other regions within The
Netherlands, 20 isolates from Australian patients (kind gift of
B. Dwyer, Clinical Pathology Laboratory, Fairfield Infectious
Diseases Hospital, Victoria, Australia), isolates from seven
Dutch patients who did not fulfil the ATS criteria and in whom
the isolation of M. kansasii was considered to reflect colonisa-
tion, and three isolates of environmental origin, were also
tested with the INNO-LiPA mycobacteria test.
Immunological investigation
Blood was obtained for immunological evaluation from five
patients who remained alive and could be contacted at the
time of this study. The protocol (P207 ⁄ 99) was approved by the
Institutional Review Board of Leiden University Medical
Center. Five heparinised tubes (9 mL each) and two lipopoly-
saccharide-free tubes (4 mL each) of venous blood were
obtained by standard methods. Peripheral blood mononuclear
cells (PBMCs) were isolated by density centrifugation and
tested immediately or frozen in RPMI medium (Gibco, Paisley,
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UK) containing fetal calf serum 20% v ⁄v and dimethylsulph-
oxide 20% v ⁄v for later use. Whole blood assays were started
on the day of blood sampling. For comparison, blood cells
obtained from healthy non-BCG-vaccinated blood donors were
included in all assays. Written informed consent was obtained
from all patients and control subjects.
Antigen-stimulated interferon-c production
Antigen-specific T-cell responses to various mycobacterial
antigens were evaluated by 6-day PBMC cultures, with IFN-c
production being measured with an ELISA technique (Ucy-
Tech, Utrecht, The Netherlands), as well as by 20-h PBMC
cultures for enumeration of IFN-c-producing antigen-specific
T-cells with an enzyme-linked immunospot assay (ELISPOT).
The following antigens were tested: purified protein derivative
(PPD), M. tuberculosis sonicate, short-term culture filtrate,
M. avium sonicate, and the common mycobacterial antigen
Ag85B. The source of these antigens, the concentrations used,
the culture techniques and measures of T-cell activation have
been described elsewhere [18].
FACS analysis
Fresh PBMCs were washed with phosphate-buffered saline
containing bovine serum albumin 0.2% w ⁄v and incubated
with phycoerythrin-conjugated monoclonal antibodies direc-
ted against IFN-c receptor 1 (IFN-cR1) (Genzyme, Cambridge,
MA, USA), IFN-cR2, tumour necrosis factor alpha receptor 1
(TNF-aR1) or TNF-aR2 (Caltag Laboratories, Burlingame, CA,
USA), and fluorescein isothiocyanate-conjugated antibodies
directed against CD14 (DAKO, Glostrup, Denmark). For each
sample, 104 cells were analysed with a FACScalibur (Becton
Dickinson, Mountain View, CA, USA). In addition, receptor
expression on CD14-positive cells was determined.
To generate phytohaemagglutinin T-cell blasts, PBMCs (106
cells ⁄mL) were incubated for 10 days in 24-well plates in
standard Iscoves Modified Dulbecco Medium (IMDM; Life
Technologies, Paisley, UK) supplemented with pooled com-
plement-inactivated human serum 10% v ⁄v, phytohaemag-
glutinin 2 lg ⁄mL and recombinant interleukin-2 (IL-2) (Chir-
on, Amsterdam, The Netherlands) at a final concentration of
25 U ⁄mL. Cell surface expression of IL-12Rb1 and IL-12Rb2,
IL-18R and IFN-cR1 by phytohaemagglutinin blasts was
analysed by labelling 0.5–2 · 105 T-cell blasts 3 days after
stimulation, followed by measurement on a FACScalibur, as
described previously [19,20].
Stimulation of whole blood
Blood collected in endotoxin-free tubes (Endotube ET; Chro-
mogenix, Milan, Italy) was diluted five to ten-fold in IMDM
and stimulated for 18 h with 1–100 ng ⁄mL lipopolysaccharide,
M. tuberculosis or M. avium sonicate (final concentration
10 lg ⁄mL; a kind gift of A. Kolk, Royal Tropical Institute,
Amsterdam, The Netherlands) in the presence or absence of
IFN-c (5–5000 IU ⁄mL). Levels of IL-12 p40, IL-12 p70 (R & D
Systems, Abingdon, UK), IL-10, IL-6 and TNF-a (Central
Laboratory of The Netherlands Red Cross Blood Transfusion
Service, Amsterdam, The Netherlands) were determined by
ELISA in pooled supernatants of triplicate wells. TNF-a
response was analysed by incubating whole blood diluted
five-fold with increasing amounts of TNF-a (10–100 ng ⁄mL)
and measurement of IL-6 production in supernatants after
culture for 18 h.
IL-12 and IL-18 responsiveness of T-cells
Responsiveness to IL-12, IL-18 and combinations of these
was determined by stimulation of 5 · 104 phytohaemagglu-
tinin blasts for 72 h with mitogenic antibodies in the
presence or absence of recombinant human IL-12 (final
concentrations 40, 200 and 1000 pg ⁄mL; R & D Systems) or
IL-18 (final concentration 50 ng ⁄mL; Medical and Biological
Laboratories, Nagoya, Japan) or in the presence of both, as
described previously [21]. IFN-c levels in pooled superna-
tants of triplicate wells were determined by ELISA. The
cultures were incubated in the presence of (3H)thymidine
(0.5 lCi ⁄well) for an additional 16 h to measure cellular
proliferation.
IFN-c responsiveness of monocytes
PBMCs were incubated overnight in hydron-coated wells to
prevent adherence of the monocytes, with different concen-
trations of IFN-c (0–100 IU ⁄mL). Cells were washed and
stained with fluorescein isothiocyanate-conjugated anti-CD64
and phycoerythin-conjugated anti-CD14. CD64 expression on
CD14-positive cells was analysed with a FACScalibur, as
described above.
Statistical analysis
The results of the immunological assays in patients and control
subjects were compared non-parametrically with the Mann–
Whitney test.
RESULTS
Clinical characteristics of patients with
M. kansasii pneumonia
Between May 1991 and August 2001, 17 patients
diagnosed with M. kansasii pneumonia according
to the ATS criteria had visited the Regional Health
Authority in South Limburg at least once during
the course of their treatment. Tables 1 and 2
describe the demographic and clinical character-
istics of these patients. The mean age at diagnosis
was 50.6 ± 14.3 years, and 13 (76%) patients were
men. All patients were native Dutch, except
patient 8, who was born in Indonesia. Although
the profession was not retrievable for all patients,
the work of five patients (4, 5, 7, 9 and 15)
involved intensive contact with water systems.
No predisposing factor could be identified in
patients 12 and 16.
Two patients were asymptomatic at the time of
diagnosis, which was made following routine
chest radiography. The remaining 15 patients had
been symptomatic for a mean of 3.9 ± 3.1 months
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(median 3; range 0.5–12). All symptomatic pa-
tients complained of coughing, accompanied in
some by haemoptysis (4 ⁄ 15 patients), weight loss
(10 ⁄ 15) and ⁄ or fever (7 ⁄ 15). Total lymphocyte
counts were normal (> 103 ⁄ lL) at the time of
diagnosis. All patients fulfilled the ATS criteria
for the type and number of positive cultures, with
a mean of 3.6 (range 2–10) positive cul-
tures ⁄patient (Table 1). Initial treatment consisted
of isoniazid, rifampicin and pyrazinamide, with
the latter being replaced with ethambutol, clarith-
romycin or a fluoroquinolone after culture results
were known, for a total mean duration of treat-
ment of 13.1 ± 4.6 months. One patient died
during treatment. None of the 17 patients had
been included in any of the other patients’ contact
investigations. Also, no temporal or spatial epi-
demiological link could be identified retrospec-
tively between the patients.
M. kansasii genotyping
The internally transcribed spacer sequence geno-
types were determined and MPTR RFLP typing
was performed to assess the evolutionary lineage
of these clinically significant M. kansasii isolates.
All 17 clinical isolates from this study were of the
INNO-LiPA MKA-I type. The clinical isolates
from other regions in The Netherlands and
Australia were also of the INNO-LiPA MKA-I
Table 1. Characteristics of 17 patients with Mycobacterium kansasii pneumonia
No. Sex
Age at
diagnosis
(years)
Year of
diagnosis Profession
Smoking
(cig./day)
Other predisposing
factors
Special
characteristics
1 F 61.2 1991 House-keeper > 20 COPD
2 M 70.3 1991 Retired (unknown) NA Poor general condition
3 M 63.9 1991 Graphic designer 20 COPD
4 M 62.7 1992 Farmer 30 DM, alcohol
5a M 39.6 1992 Plumber 5–10 Recurrent airways infections
6 M 48.9 1992 Bus driver > 25 COPD
7 M 50.2 1993 Sand-blaster 25 None
8 M 37.4 1993 Retired (unknown) > 25 COPD, drugs
9a M 44.7 1993 Central heating worker 15 COPD
10 M 35.2 1993 Jobless > 25 Drugs, alcohol, bronchitis
11 F 35.8 1993 Administrator > 20 Recurrent pneumothorax
12a M 47.7 1995 Administrator 0 None Marathon runner
13a M 71.5 1997 Retired administrator 15 None
14 M 76.3 1999 Retired mine worker 0 COPD, silicosis
15 M 44.3 2000 Laundry worker 25 COPD
16a F 39.5 2000 Primary school teacher 0 None Nail–patella syndrome
17 F 31.4 2001 Bank employee 25 None
COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.
aPatient who participated in the immunological evaluation.
Table 2. Clinical features of 17 patients with Mycobacterium kansasii pneumonia
No.
Symptoms
(months) Haemoptysis
Weight
loss Fever
Chest
X-rayb Cavities
TST
(mm)
PPD-K
skin test
(mm) Ziehl–Neelsen
Culture of specimen
(no. of positive cultures);
histology with granulomas (+)
1 2 + 1 15 ND + Sputum (3)
2 3 + + 2 ND ND + Sputum (2)
3 6 + 2 ND ND + Sputum (2)
4 None 1 + ND ND + BAL and sputum (4); histology (+)
5a 5 + + + 2 + 10 20 + Sputum (5)
6 12 + + + 2 + 10 15 + BAL and sputum (3)
7 0.5 + + 2 + 0 0 + Sputum (2)
8 6 + + 2 + ND ND + Sputum (> 1, not quantified)
9a 1 + 2 + ND ND – Biopsy and sputum (3); histology (+)
10 2 + + 1 + 0 5 + BAL and sputum (3)
11 None 1 0 0 + BAL and biopsy (2); histology (+)
12a 1.3 + 1 + 0 8 + BAL and sputum (10)
13a 6 + + 1 + ND ND + Sputum (3)
14 4.5 2 + ND ND + Sputum (3)
15 2 2 + 40 ND + Sputum (3)
16a 6 1 + 25 ND + Sputum (5)
17 1 + + 1 15 ND + BAL and sputum (7)
BAL, bronchoalveolar lavage; PPD-K, tuberculin of M. kansasii; TST, tuberculin skin test; ND, not done.
aPatient who participated in the immunological evaluation.
bOne- or two-sided infiltrates.
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type, except one isolate that was INNO-LiPA
MKA-II. One of the three environmental isolates
was INNO-LiPA MKA-II, and two were INNO-
LiPA MKA-III.
Fig. 1 shows the MPTR RFLP patterns of the
15 patient isolates available for typing (the iso-
lates of patients 2 and 4 had insufficient growth
for fingerprinting), demonstrating that the pat-
terns were identical. For clarity, only some of the
control strains are shown: two Dutch clinical
isolates from another study (one MKA-I and one
MKA-II), two of the 20 clinical isolates from
Australia (all isolates were MKA-I and had
identical MPTR patterns), three environmental
M. kansasii strains and one M. tuberculosis strain.
Six of seven isolates from patients colonised with
M. kansasiiwere MKA-I, and one was MKA-II (not
shown).
Interestingly, all INNO-LiPA MKA-I isolates
had identical MPTR patterns irrespective of the
geographical origin, suggesting a clonal origin of
the causative M. kansasii isolates. The exception,
which was of the INNO-LiPA type MKA-II,
showed a strongly deviant MPTR RFLP pattern,
which was identical to that of the INNO-LiPA
MKA-II environmental isolate from another geo-
graphical region.
Evaluation of innate and adaptive cell-mediated
immunity
In view of the identical fingerprint patterns of the
causative M. kansasii strains in the absence of a
common source of exposure, it was assumed that
this particular strain was widespread in the
environment in that region, with exposure being
rather common. If that were true, these patients
could have become ill either because of exposure
to a large inoculum or because they had an
unrecognised cellular immune defect. The lack of
knowledge about the source of infection preclu-
ded the study of circumstances affecting inocu-
lum size. Since individuals with defects in type-1
immunity are highly susceptible to infection with
non-tuberculous mycobacteria [11], type-1 im-
mune responses and the expression of relevant
cytokine receptors were investigated in patients
with M. kansasii infection. For this purpose, blood
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Fig. 1. RFLP fingerprint patterns ofMycobacterium kansasii isolates with the major polymorphic tandem repeat (MPTR) as a
probe and PvuII as restriction enzyme. The INNO-LiPA Mycobacteria test was used to identify the M. kansasii internally
transcribed spacer sequence genotypes (see Methods), indicated by MKA type I, II or III. The source and origin of each
isolate are indicated. Patient number refers to the numbering as used in Table 1. For comparison, the results of one
M. tuberculosis reference strain, two other clinicalM. kansasii isolates from patients in other regions within The Netherlands
(one MKA-I and one MKA-II) and two from Australian patients (MKA-I), as well as three isolates of environmental origin,
are shown. The MTPR pattern of the Australian isolates was not different from that of the other MKA-I isolates; the
difference in quality of the bands was explained by prolonged storage of the DNA.
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was obtained from five available patients
(patients 5, 9, 12, 13 and 16 in Table 1, thus
including both patients with no recognised risk
factors). No selection criteria were used, other
than availability and consent. The patients avail-
able for immunological evaluation did not differ
significantly from untested patients with regard
to age, sex or extent of disease.
Antigen-specific immune responses
IFN-c production by PBMCs obtained from sub-
jects infected with M. kansasii in response to
M. tuberculosis sonicate, M. avium sonicate or
Ag85B did not differ from the responses of PBMCs
frompersons infectedwithM.marinum orM. tuber-
culosis, or of healthy controls (Table 3). IFN-c
responses to PPD and short-term culture filtrate
of M. tuberculosis were significantly higher in
tuberculosis patients than in healthy controls and
patients infected with M. kansasii. IFN-c ELISPOT
results in response to PPD were higher in tuber-
culosis patients, but were not statistically different
between groups. These findings reflect the broad
cross-reactivity of immune responses to complex
antigens such as PPD or mycobacterial sonicates,
or to a recombinant protein antigen (Ag85B) that
has a very high level of homology between
mycobacterial species [22]. Together, these results
gave no indication of decreased antigen-specific
IFN-c responses to mycobacterial antigens.
FACS analysis of cytokine receptor expression
Monocytes of all five patients expressed normal
levels of IFN-cR1, IFN-cR2, TNF-aR1 and TNF-
aR2, when compared with healthy controls. Simi-
larly, the expression of IL-12Rb1, IL-12Rb2 and
IL-18R on activated T-cell blasts of the patients
was not different from that of controls (data not
shown).
Evaluation of cell-mediated immunity
The functional responses to various cytokines and
stimuli of the innate immune system were eval-
uated by incubating whole blood with lipopoly-
saccharide or mycobacterial sonicates, in the
presence or absence of IFN-c. The resulting levels
of TNF-a and IL-10 were in the same range for
patients and controls (Table 4). IFN-c-induced
up-regulation of TNF-a expression and down-
regulation of IL-10 production by lipopolysaccha-
ride-stimulated cells were normal (data not
shown). PBMCs were incubated with increasing
amounts of IFN-c, and the expression of CD64,
which is regulated by IFN-c, was measured. All
five patients showed a dose-dependent up-regu-
lation of CD64 expression within the normal
range (Table 4).
The levels of IL-6 production in whole blood in
response to TNF-a in patients and normal con-
trols were also in the same range. Evaluation of
both the absolute IFN-c level and the stimulation
indices of IFN-c production by anti-CD3 ⁄ anti-
CD28-stimulated T-cell blasts in response to IL-12
and ⁄ or IL-18 revealed no abnormalities in
patients compared with healthy controls (Table 4
and data not shown). Taken together, these data
revealed no defects in type-1 immune responses
in these five patients with previous pulmonary
M. kansasii infection.
Table 3. IFN-c production and enumeration of IFN-c producing cells in response to mycobacterial antigens
IFN-c production (pg/mL)a
IFN-c ELISPOTb
PPDPPD MTB sonicate STCF M. avium sonicate Ag85B
M. kansasii infection (n = 5) 622 ± 778 2892 ± 3995 683 ± 659 1572 ± 1806 490 ± 307 30 ± 28
M. marinum infection (n = 7) 761 ± 711 2421 ± 1173 1180 ± 805 2144 ± 1610 1060 ± 883 66 ± 71
Other non-tuberculous
mycobacterial infection (n = 2) 490 ± 692 1205 ± 1045 462 ± 653 1242 ± 484 117 ± 88 47 ± 47
Tuberculosis (n = 4) 2256 ± 995c 3494 ± 1155d 3302 ± 1611e 2285 ± 1074 546 ± 231 140 ± 134
Healthy controls (n = 5) 28 ± 15 1017 ± 563 203 ± 172 912 ± 499 329 ± 172 22 ± 18
ELISPOT, enzyme-linked immunospot assay; MTB, M. tuberculosis; PPD, purified protein derivative; STCF, short-term culture filtrate of M. tuberculosis.
aAfter 6 days of culture.
bAfter 20 h of culture. ELISPOT results are adjusted for background values and expressed as mean spot-forming units (SFU)antigen ) (mean SFU + (3 · SEM))medium [18].
Positive values indicate a positive response.
cp 0.02 for comparison with M. kansasii and with healthy controls.
dp 0.02 for comparison with healthy controls.
ep < 0.03 for comparison with each of the other groups.
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For comparison, the mean results for seven
other patients, who lived in different regions
within The Netherlands and had been diagnosed
with M. kansasii pneumonia or isolated pulmon-
ary infection caused by another non-tuberculous
mycobacterial species, and for the corresponding
controls are shown in Table 4. These patients had
been referred to Leiden University Medical
Center for evaluation of the type-1 immune
system. As in the five patients from the present
study, no abnormalities or deficiencies in type-1
immunity were identified.
DISCUSSION
The outcome of infection with M. kansasii is
determined by the complex interplay between
the characteristics of the host, the pathogen and
the environment. While host susceptibility to non-
tuberculous mycobacteria is a prominent feature
of patients with defects in the cellular immune
system [23–25], the factors that contribute most to
the pathogenesis of M. kansasii pneumonia in
apparently healthy persons are not known.
The clinical presentation of M. kansasii pneu-
monia in the patients described in this study
varied from completely asymptomatic to exten-
sive lung destruction accompanied by systemic
symptoms. Most patients had bilateral infiltrates
and ⁄ or cavitation, similar to the findings in
previous studies [26], but the severity and dur-
ation of symptoms did not correlate with the
extent of radiographic abnormalities. At least one
of the risk factors recognised previously, such as
chronic lung disease or a history of smoking, was
present in all but two patients, indicating that
abnormal lung anatomy or function is associated
with susceptibility to invasive infection with
M. kansasii, but may not be essential. The
observed characteristics underscore the similarit-
ies between M. kansasii-induced pneumonia and
classical tuberculosis.
With regard to the role of M. kansasii in
pathogenesis, it was recognised > 40 years previ-
ously that M. kansasii is a heterogeneous species
[27]. More recently, five subtypes have been
identified by genotyping of the 16S)23S intergen-
ic spacer region [28]. With some overlap, mainly
in genotype MKA-II, which has been associated
with infection in immunosuppressed or AIDS
patients [29,30], clinical and environmental iso-
lates are distinct genotypically, which suggests
phenotypic differences that determine the ability
to cause disease in humans. Genotype MKA-I is
the most common type found among clinical
isolates [28,30] and has been isolated only rarely
Table 4. Evaluation of type-1 cellular immunity
Response to LPSa
CD64 up-regulation (ratio)
Response to IFN-cb
IFN-c production (SI) Response to IL-12cTNF-a production (pg/mL) IL-10 production (pg/mL)
Patientsd
Patient 5 1067 224 3.37 9.85
Patient 9 848 204 2.84 2.23
Patient 12 774 107 3.21 2.10
Patient 13 2429 347 2.84 1.82
Patient 16 576 605 2.47 1.85
Mean ± SD 1139 ± 742 297 ± 192 2.95 ± 0.35 3.57 ± 3.51
Controls Controls
C1 1277 230 3.19 C4 3.93
C2 2430 280 2.54 C5 3.94
C3 802 443 4.03 C6 2.00
Mean ± SD 1503 ± 837 318 ± 111 3.25 ± 0.75 3.29 ± 1.12
Other patients
with pneumonia
caused by
non-tuberculous
mycobacteriae
n = 5 n = 5 n = 7 n = 6
Mean ± SD 646 ± 395 230 ± 194 4.14 ± 1.72 4.42 ± 1.76
Controls n = 5 n = 5 n = 7 Controls n = 6
Mean ± SD 616 ± 287 157 ± 134 3.88 ± 1.73 5.22 ± 2.54
aTNF-a and IL-10 production of whole blood in response to 10 ng ⁄mL lipopolysaccharide (LPS).
bCD64 expression on monocytes is expressed as the ratio of the median fluorescence of stimulated (100 U ⁄mL of IFN-c) over unstimulated cells.
cIL-12-mediated IFN-c production by anti-CD3 ⁄ anti-CD28-treated T-cell blasts is expressed as the ratio of IFN-c production by cells in the presence or absence of IL-12
(1 ng ⁄mL). SI, stimulation index. The healthy controls in this assay differ from the ones used in the assays analysing the LPS and IFN-c responses.
dNumbering according to Table 1.
eThese patients were from other regions in The Netherlands; their clinical data are not described in the present paper. The causative species were: M. abscessus (n = 1),
M. avium-intracellulare (n = 3), M. kansasii (n = 2), and M. malmoe¨nse (n = 1).
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from the environment (unpublished data).
Indeed, all patient isolates in this study, as well
as all Australian clinical isolates, were of geno-
type MKA-I. More strikingly, the MPTR finger-
print patterns were identical. MPTR is considered
a suitable method for investigating M. kansasii
isolates, as it gives distinct patterns in isolates of
different origin, whereas other typing methods
result in identical fingerprints [16]. However,
MPTR does not differentiate between genotype
MKA-I isolates from different sources, since all
MKA-I isolates shared the same MPTR fingerprint
pattern. In accordance with this finding, identical
genotypes (by analysis of large-restriction-frag-
ment polymorphisms) were found in 11 patients
in an industrial zone in Japan [31]. Together, these
data support the view that one genotype or
genetic lineage of M. kansasii can be pathogenic
for non-immunocompromised hosts. Interest-
ingly, all isolates obtained from patients colonised
with M. kansasii were also of genotype MKA-I or
MKA-II, i.e., those associated with invasive infec-
tion. This observation strongly supports the
hypothesis that colonisation and invasive infec-
tion represent two different phases of the same
infection.
Large geographical differences in the incidence
of M. kansasii pneumonia exist, but it is unclear
whether this results from the spatially selective
presence of the pathogen or circumstances lead-
ing to effective transmission. An association
between dusty occupations and M. kansasii infec-
tions has been demonstrated [32]. The prevalence
of (previously) heavily industrialised regions
suggests a role for air quality. In the present
study, only one patient was a former mine
employee with silicosis and chronic lung disease.
In view of the fact that water systems are the
presumed reservoir of M. kansasii, it is interesting
that the profession of several patients involved
intensive contact with water systems. It has not
been demonstrated formally whether human
infection with M. kansasii originates from artificial
or natural sources. Presumably, M. kansasii bac-
teria isolated today underwent long-term evolu-
tionary divergence and existed long before there
were artificial water systems, and it is therefore
reasonable to assume that a true natural reservoir
exists. M. kansasii has been isolated, albeit rarely,
from natural water reservoirs, soil and animal
sources [33–36]. M. kansasii is a rare pathogen
in animals, but manifest infection has been
diagnosed in various animal species [36,37],
including cattle (J. Pollock, personal communica-
tion). Most of the patients with M. kansasii
pneumonia had regular and intensive contact
with various animal species, but no common
exposure could be identified. Thus far, there is no
proof of zoonotic transmission. It is generally
assumed that the route of infection is by inhala-
tion, but without knowledge of the precise source
of infection, nothing can be said about the
circumstances leading to formation of M. kans-
asii-containing particles of an infective size. This
lack of knowledge precludes preventive meas-
ures.
It is not known why patients who expectorate
high numbers of M. kansasii in their sputum do
not transmit the infection. An explanation could
be that these are killed effectively by the innate
immune system. Secondary cases of M. kansasii
pneumonia have been described sporadically [38],
but true human-to-human transmission would be
impossible to prove, since a close contact who
develops M. kansasii pneumonia as an apparent
secondary case has, by definition, been exposed to
the same environment harbouring the unrecog-
nised source. Isolation of source patients and
contact investigations are not indicated, but it
would take several weeks from the time a patient
presents with smear-positive pulmonary disease
before M. kansasii could be identified. The appli-
cation of molecular diagnostic methods, such as a
PCR for the M. tuberculosis complex or for bacter-
ial DNA of environmental mycobacteria [39,40],
may lead to a more rapid and specific diagnosis
and prevent the unnecessary costs and turmoil
that come with the suspicion of contagious tuber-
culosis.
In the five available patients, including those
without known risk factors, innate and antigen-
specific cellular immune responses were studied
in some detail, but no differences were found
compared with control subjects. It cannot be
concluded definitively from these findings that
antigen-specific immune responses were normal,
because these were tested after an interval
ranging from 0 to 10 years (average 7 years)
following diagnosis, and thus may not reflect
the immune status at the time of active disease.
However, tuberculin skin test results obtained at
the time of diagnosis were positive in six of the
ten patients who underwent skin testing, there-
by indicating a capacity to display an adequate
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delayed-type hypersensitivity response. In a
previous study of patients with M. kansasii
disease, 16 (59%) of 27 patients had a positive
tuberculin skin test response [41].
The evaluation of the innate immune system,
which can be assumed to reflect an intrinsic and
unchanging characteristic of an individual, also
revealed no differences compared with healthy
control subjects. While more subtle or completely
distinct immune defects could exist that escaped
detection by the methods used, none of these
patients had any unusual infection before or after
diagnosis of M. kansasii pneumonia. Increasing
numbers of cytokines, cytokine receptors and
intracellular signal-transducing molecules are rec-
ognised as contributing to type-1 immunity,
which is essential for resistance against intracel-
lular pathogens such as mycobacteria (e.g., IL-5,
IL-23, IL-27), and these could be candidates for
further study.
The identical genotype and MPTR patterns of
the isolates, and an absence of defects in host
defence, suggest that a certain genotype of
M. kansasii possesses virulence factors underly-
ing its ability to cause disease in subjects
without immune defects. Thus far, no virulence
factors of M. kansasii have been described.
Interestingly, M. kansasii and M. marinum share
with M. tuberculosis the genes coding for ESAT-6
and CFP-10 [42–45]. These small proteins are
immunodominant antigens encoded by the RD1
genomic region of M. tuberculosis and M. bovis,
which was deleted at an early stage during the
attenuation of M. bovis to the vaccine strain
M. bovis Bacille Calmette Gue´rin (BCG) [42,46].
Recent studies showed that deletion of the esat-6
gene in M. bovis [47] or deletion of RD1 in
M. tuberculosis resulted in decreased virulence
[48], while reinsertion of RD1 into BCG or
M. microti increased virulence [49] in experi-
mental animal models, which is in agreement
with the notion that RD1-encoded proteins such
as ESAT-6 and CFP-10 contribute to virulence.
The function of these proteins is not known, but
CFP-10 was recently demonstrated to have
immunomodulating effects on mononuclear cells
in vitro through effects on TNF-a production
and nitric oxide synthesis [50]. It is not known
whether the esat-6 and cpf-10 genes are present
in all M. kansasii genotypes, clinical and envi-
ronmental alike, or whether they are always
expressed.
In conclusion, a study of the innate and
adaptive immune systems of 17 patients from a
limited geographical area who were diagnosed
with M. kansasii pneumonia revealed none of the
abnormalities in the type-1 immune response
that have been associated previously with infec-
tion by non-tuberculous mycobacteria and sal-
monellae. The causative strains had identical
genotypes and MPTR fingerprint patterns, but an
epidemiologial connection between these
patients or a common factor of exposure could
not be identified. These findings are compatible
with the presence of virulent strains of M. kansasii
in geographically confined environmental
sources in a setting amenable to effective trans-
mission to humans.
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